MBX Biosciences (MBX) Non-Current Assets (2023 - 2026)

MBX Biosciences (MBX) has 4 years of Non-Current Assets data on file, last reported at $4.2 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets rose 152.42% year-over-year to $4.2 million; the trailing twelve-month figure through Mar 2026 stood at $12.7 million (up 161.68% YoY), and the FY2025 full-year result was $3.6 million, up 188.63% from the prior year.
• Non-Current Assets improved to $4.2 million in Q1 2026, from $3.6 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $4.2 million in Q1 2026 to a low of $715000.0 in Q4 2023.
• A 4-year average of $2.2 million and a median of $2.0 million in 2025 frame the typical range for Non-Current Assets.
• Across the five-year window, Non-Current Assets soared 74.69% in 2024 and soared 188.63% in 2025, its largest moves.
• Tracing MBX's Non-Current Assets over 4 years: stood at $715000.0 in 2023, then soared by 74.69% to $1.2 million in 2024, then soared by 188.63% to $3.6 million in 2025, then climbed by 15.53% to $4.2 million in 2026.
• Business Quant data shows MBX's Non-Current Assets at $4.2 million in Q1 2026, $3.6 million in Q4 2025, and $2.6 million in Q3 2025.